Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 11, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Board Appointments

Lynn D. Bleil Appointed to Board of Directors Michael G. Raab Named Lead Independent Director CRANBURY, N.J., Sept. 11, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global...
September 10, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Regulatory and Clinical Updates for AT-GAA in Pompe Disease

CRANBURY, N.J., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
August 31, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2018

CRANBURY, N.J., Aug. 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced upcoming presentations at two investor conferences in September. Bradley Campbell, President and...
August 10, 2018 16:05 ET | Source: Amicus Therapeutics, Inc.

FDA Approves Galafold™ (migalastat) for the Treatment of Certain Adult Patients with Fabry Disease

First Precision and First Oral Medicine for Fabry Disease Approved for 348 Amenable GLA Variants Galafold is the First New Treatment Option for Fabry Disease in the U.S. in 15+ Years Amicus...
August 07, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces Second Quarter 2018 Financial Results and Corporate Updates

2Q18 Net Product Sales of $21.3M Driven by Galafold® (Migalastat) Expansion Company Increases FY18 Global Galafold Revenue Guidance to $80M-$90M Pompe Clinical, Regulatory and Manufacturing...
July 31, 2018 07:30 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Announce Second Quarter 2018 Financial Results on August 7, 2018

CRANBURY, N.J., July 31, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD) today announced that the Company will host a conference call and live audio webcast on Tuesday, August 7, 2018 at...
June 26, 2018 16:05 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease

CRANBURY, N.J., June 26, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
June 08, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Appoints President and COO Bradley L. Campbell to Board of Directors

CRANBURY, N.J., June 08, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD), a global biotechnology company focused on discovering, developing and delivering novel medicines for rare...
June 01, 2018 07:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics to Present at Goldman Sachs 39th Annual Global Healthcare Conference

CRANBURY, N.J., June 01, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics, Inc. (Nasdaq:FOLD) announced today that John F. Crowley, Chairman and Chief Executive Officer, will participate in a corporate...
May 30, 2018 00:00 ET | Source: Amicus Therapeutics, Inc.

Amicus Therapeutics Launches Galafold® (Migalastat) for Fabry Disease in Japan

CRANBURY, N.J. and TOKYO, May 30, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) has initiated the commercial launch of the oral small molecule pharmacological chaperone Galafold®...